PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and opportunities in the field of psychedelic...
With a rise in clinical research and trials into the use of psychedelic therapies for mental health, and with a number of countries changing regulations around...
The world’s first postgraduate course on psychedelics has been launched at the University of Exeter – an interdisciplinary programme for healthcare workers, therapists and others to...
Filament Health and PharmAla Biotech Holdings Inc.
With a high demand for psychedelic facilitators, Cybin Inc.
With years of experience in developing cannabinoid medicines, Australia-based MGC Pharmaceuticals will now be branching into psychedelic medicine development.
A group of 13 individuals have become the first people to be licensed to facilitate psilocybin experiences in the United States outside of clinical trials in...
A new collaboration between Emyria and Australia’s specialist trauma service, the PAX Centre, is aiming to develop a scalable MDMA-assisted therapy model for patients with complex...
Optimi Health has entered into a long-term distribution agreement with Mind Medicine Australia to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules.
PharmAla Biotech Holdings has been named the exclusive supplier of both GMP and engineering MDMA to Awakn LS Europe Holdings Limited.